The Effects of Device-Based Cardiac Contractility Modulation Therapy on Left Ventricle Global Longitudinal Strain and Myocardial Mechano-Energetic Efficiency in Patients with Heart Failure with Reduced Ejection Fraction.
cardiac contractility modulation
global longitudinal strain
heart failure with reduced ejection fraction
myocardial mechano-energetics efficiency
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
04 Oct 2022
04 Oct 2022
Historique:
received:
17
08
2022
revised:
29
09
2022
accepted:
01
10
2022
entrez:
14
10
2022
pubmed:
15
10
2022
medline:
15
10
2022
Statut:
epublish
Résumé
Virtually all patients with heart failure with reduced ejection fraction have a reduction of myocardial mechano-energetic efficiency (MEE). Cardiac contractility modulation (CCM) is a novel therapy for the treatment of patients with HFrEF, in whom it improves the quality of life and functional capacity, reduces hospitalizations, and induces biventricular reverse remodeling. However, the effects of CCM on MEE and global longitudinal strain (GLS) are still unknown; therefore, this study aims to evaluate whether CCM therapy can improve the MEE of patients with HFrEF. We enrolled 25 patients with HFrEF who received an Optimizer Smart implant (the device that develops CCM therapy) between January 2018 and January 2021. Clinical and echocardiographic evaluations were performed in all patients 24 h before and six months after CCM therapy. At six months, follow-up patients who underwent CCM therapy showed an increase of left ventricular ejection fraction (30.8 ± 7.1 vs. 36.1 ± 6.9%; CCM therapy increased left ventricular performance, improving left ventricular ejection fraction, GLS, as well as MEE and MEEi.
Sections du résumé
BACKGROUND
BACKGROUND
Virtually all patients with heart failure with reduced ejection fraction have a reduction of myocardial mechano-energetic efficiency (MEE). Cardiac contractility modulation (CCM) is a novel therapy for the treatment of patients with HFrEF, in whom it improves the quality of life and functional capacity, reduces hospitalizations, and induces biventricular reverse remodeling. However, the effects of CCM on MEE and global longitudinal strain (GLS) are still unknown; therefore, this study aims to evaluate whether CCM therapy can improve the MEE of patients with HFrEF.
METHODS
METHODS
We enrolled 25 patients with HFrEF who received an Optimizer Smart implant (the device that develops CCM therapy) between January 2018 and January 2021. Clinical and echocardiographic evaluations were performed in all patients 24 h before and six months after CCM therapy.
RESULTS
RESULTS
At six months, follow-up patients who underwent CCM therapy showed an increase of left ventricular ejection fraction (30.8 ± 7.1 vs. 36.1 ± 6.9%;
CONCLUSIONS
CONCLUSIONS
CCM therapy increased left ventricular performance, improving left ventricular ejection fraction, GLS, as well as MEE and MEEi.
Identifiants
pubmed: 36233734
pii: jcm11195866
doi: 10.3390/jcm11195866
pmc: PMC9573486
pii:
doi:
Types de publication
Journal Article
Langues
eng
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Pacing Clin Electrophysiol. 2022 May;45(5):639-648
pubmed: 35262210
Eur J Heart Fail. 2017 Mar;19(3):307-313
pubmed: 27891719
Curr Cardiol Rep. 2021 Feb 16;23(3):18
pubmed: 33594493
ESC Heart Fail. 2022 Aug;9(4):2291-2300
pubmed: 35481670
Curr Cardiol Rep. 2022 Jun;24(6):711-730
pubmed: 35353328
ESC Heart Fail. 2020 Oct;7(5):2922-2932
pubmed: 32700809
J Card Fail. 2007 Mar;13(2):137-42
pubmed: 17395055
Physiol Rev. 2009 Oct;89(4):1153-76
pubmed: 19789379
J Am Soc Echocardiogr. 2015 Jan;28(1):1-39.e14
pubmed: 25559473
Curr Opin Cardiol. 2019 Mar;34(2):147-155
pubmed: 30633076
J Am Soc Echocardiogr. 2019 Jan;32(1):1-64
pubmed: 30282592
Heart Fail Rev. 2021 Mar;26(2):217-226
pubmed: 32852661
Am J Physiol Heart Circ Physiol. 2002 May;282(5):H1642-7
pubmed: 11959626
Heart Fail Rev. 2001 Jan;6(1):27-34
pubmed: 11248765
Eur J Heart Fail. 2006 Jan;8(1):7-15
pubmed: 16202650
Eur J Heart Fail. 2019 Jan;21(1):14-22
pubmed: 30485591
Circulation. 2007 Feb 20;115(7):918-27
pubmed: 17309938
J Am Coll Cardiol. 2007 May 29;49(21):2120-8
pubmed: 17531662
J Am Coll Cardiol. 2002 Apr 17;39(8):1264-8
pubmed: 11955842
J Int Med Res. 2020 Oct;48(10):300060520962910
pubmed: 33044118
Eur J Heart Fail. 2019 Sep;21(9):1103-1113
pubmed: 30652394
J Am Coll Cardiol. 2008 May 6;51(18):1784-9
pubmed: 18452785
J Clin Med. 2020 Aug 19;9(9):
pubmed: 32824903
J Am Soc Echocardiogr. 2002 Feb;15(2):167-84
pubmed: 11836492
Cardiology. 2008;110(4):230-7
pubmed: 18073477
Braz J Med Biol Res. 2013 Sep;46(9):803-8
pubmed: 24036912
J Pers Med. 2022 Jun 18;12(6):
pubmed: 35743780
Heart Vessels. 2007 Jul;22(4):237-44
pubmed: 17653517
Am Heart J. 2005 Jan;149(1):152-8
pubmed: 15660047
J Cardiovasc Med (Hagerstown). 2011 Mar;12(3):223-5
pubmed: 21285738
J Clin Med. 2022 Oct 04;11(19):
pubmed: 36233734
J Clin Med. 2019 Jul 17;8(7):
pubmed: 31319598
Chest. 2022 Jun;161(6):1598-1605
pubmed: 35085589
Eur J Heart Fail. 2014 Dec;16(12):1301-9
pubmed: 25211239
Clin Transl Sci. 2009 Jun;2(3):211-5
pubmed: 20443895